FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPL
ITCI: Intra-Cellular Therapies Inc.
2019-12-23 06:59:10
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
2019-12-23 06:59:10
FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults